Loading clinical trials...
Loading clinical trials...
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Non-obese Progestin-insensitive Early-stage Endometrial Cancer and Atypical Hyperplasia Patients With Conservative Treatment
Conditions
Interventions
GnRHa
Letrozole 2.5mg
+2 more
Locations
2
China
Obstetrics and Gynecology Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Tenth People's Hospital of Tongji University
Shanghai, Shanghai Municipality, China
Start Date
July 13, 2022
Primary Completion Date
March 30, 2026
Completion Date
March 30, 2027
Last Updated
August 11, 2025
NCT07046923
NCT05129969
NCT06751329
NCT05770102
NCT07114653
NCT05316493
Lead Sponsor
Xiaojun Chen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions